SPD 535

Drug Profile

SPD 535

Alternative Names: SPD-535

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Shire
  • Class Antiplatelets; Antithrombotics; Cardiovascular therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 31 Dec 2012 Discontinued - Phase-II for Thrombosis in United Kingdom (unspecified route)
  • 08 Dec 2011 Phase-II clinical trials in prevention of Thrombosis in United Kingdom in patients with arteriovenous grafts and undergoing haemodialysis (unspecified route)
  • 20 Feb 2007 Preclinical trials in Thrombosis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top